Limerick spin-out Powervation, which raised $37m from investors including Intel Capital and Semtech, has been acquired by Rohm.

Unilever spin-out Voltea, a developer of water desalination technology, raised the funding in a round also featuring industrial products maker Pentair.

The series B funding will help KalVista, a spin-out of Vantia Therapeutics, to advance treatments for diabetes and blood disease to clinical trials.

The Novartis-backed eye disease treatment developer, which filed to go public earlier this month, has now raised almost $78m from two equity rounds.

Bima's existing investors, including Millicom and Digicel, backed the insurance platform's $38.4m series C round, taking its overall funding to more than $67m.

Eletranova Capital, which is backed by EDF and Allianz, is among the investors in a series C round for the water treatment technology developer that so far stands at $9.1m.

Leeds spinout Glucosense forms with NetScientific to commercialise blood-free test for glucose levels.